Embed Size (px)
Citation preview
The Next Frontier: Indonesia Opportunities and Challenges in the Indonesian Pharmaceutical Market - Outlook through 2016
Exclusive to CPhI South East Asia 2013
The Next Frontier: Indonesia
• Author: IMS Health
• Contact us:
Disclaimer • The analyses, their interpretation, and related information contained herein are made and provided subject to the
assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or data.
• As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.
• All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IMS HEALTH.
• © 2013 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.
© 2013 IMS Health Incorporated and its affiliates.
The Next Frontier: Indonesia
2
Rupesh Chudasama
Global Market Measurement, Asia-Pacific and China
Mobile: +61 (0) 420 903 286
Email: [email protected]
The pharmaceutical market is forecast to grow at a CAGR of 13.3% (±3.0%) between 2011 and 2016, reaching US$7,825 million by
2016
3
0%
2%
4%
6%
8%
10%
12%
14%
16%
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
2011 2012 2013 2014 2015 2016
Annual G
row
th
US$ (
million)
Total Market Sales US$* (million)
Ex–Manufacturer Prices
− Gradual progress towards the implementation of a single-payer national health insurance (NHI) system by January 2014, combining the existing health insurance schemes.
− Government efforts to upgrade the healthcare infrastructure ahead of implementation of NHI, with significant investments needed outside Java.
− Rapid expansion of the private hospital sector, including development of hospital chains and investment from foreign hospital groups.
− Overprescribing and polypharmacy will remain common, although attempts may be made to prevent misuse of antibiotics.
− Once NHI is in place, possibility of the introduction of a national formulary and more attention to rational prescribing.
− Growing pressure on prices following implementation of NHI, with the possibility of the creation of a national procurement agency.
− Expansion of field forces to boost geographic coverage.
Key Issues 2012-2016
*Constant exchange rate (Qtr II 2012)
Source: IMS Health
© 2013 IMS Health Incorporated and its affiliates.
The Next Frontier: Indonesia
To get the full exclusive report
• Attend the IMS presentation at the CPhI Southeast Asia Summit to receive the full report. Register today at www.cphi - sea.com .
The Next Frontier: Indonesia 4
© 2013 IMS Health Incorporated and its affiliates.
The Next Frontier: Indonesia
5
© 2013 IMS Health Incorporated and its affiliates.
